![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1471951
¼¼°èÀÇ ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀå : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ¼¼°è, Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå±âȸ ºÐ¼® - ¼ö±âº°, ȯÀÚ À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Fertility Services Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Procedure, Patient Type, End User, and Geography |
¼¼°è ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 329¾ï 9,000¸¸ ´Þ·¯¿¡ À̸£·¶°í ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.3%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç 2031³â¿¡´Â 671¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¹è°æ¿¡´Â »çȸÀû ¹× ȯ°æÀû ¿äÀÎ Áõ°¡¿Í ºÎÀΰú ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÀÖ½À´Ï´Ù. ü¿Ü¼öÁ¤(IVF)(IVF) °úÁ¤¿¡¼ ±â¼ú Áøº¸ÀÇ È®´ë´Â ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ Á¦°øÇÏ´Â °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ºÒÀÓ Ä¡·á ¼ºñ½º¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀº °í±â¾Ð »ê¼Ò ¿ä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.
À¯Àü¼º Áúȯ°ú ºÒÀÓÀÇ Ä¡·á´Â ÀÓ½ÅÀ» µ½´Â ºÒÀÓ Ä¡·á ¼ºñ½ºÀÇ ÀϺÎÀÔ´Ï´Ù. ³¼¼Æ÷Áú Á¤ÀÚ ÁÖÀÔ¹ý(ICSI)°ú ü¿Ü¼öÁ¤(IVF)(IVF)°ú °°Àº º¸Á¶»ý½Ä±â¼ú ±â¼ú(ART) ½ÃÀå °³Ã´Àº ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀå¿¡¼ °¡Àå Áß¿äÇÑ ¹ßÀü Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ±â¼úÀº »ýü ¿Ü¿¡¼ ¹è¾Æ¸¦ ÀÓ½ÅÇÏ°Ô ÇÏ°í °Ç°ÇÑ Àӽа¡´É¼ºÀ» ³ô¿© »ý½Ä ÀÇ·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ±× ¹ÛÀÇ Áøº¸·Î´Â Âø»ó Àü À¯ÀüÇÐÀû °Ë»ç, ¹è¾Æ µ¿°áº¸Á¸, ³ÀÚ µ¿°á µîÀÌ ÀÖ¾î ºÒÀÓ Ä¡·á¸¦ Ãß±¸ÇÏ´Â Ä¿ÇÃÀ̳ª °³Àο¡°Ô Ãß°¡ÀûÀÎ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.
2023³â ¼¼°è ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀå¿¡¼´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºÒÀÓ Ä¡·á ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ÀϺΠºÒÀÓ Ä¡·áÁ¦ÀÇ µµÀÔ°ú ±Þ¼ÓÇÑ À¯ÅëÀºÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù. ºÒÀÓ Ä¡·á¿¡¼ Á¶»ç Ȱµ¿ Áõ°¡´Â ÇâÈÄ ¸î ³âµ¿¾ÈÀÌ Áö¿ª ½ÃÀå¿¡ »õ·Î¿î ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¹Ì±¹Àº ºÏ¹Ì ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ³²³à ¸ðµÎ ºÒÀÓÁõÀ̳ª ºÎÀΰú ÁúȯÀ¸·Î À̾îÁö´Â °Ç°¿¡ ÇØ·Î¿î ½Ä»ýȰÀÇ °æÇâÀÌ °ÇØÁ®, ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÌ º¯ÈÇϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.
ü¿Ü¼öÁ¤(IVF)(IVF) ÇÁ·Î¼¼½ºÀÇ ±â¼ú Áøº¸´Â ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÃËÁø
ü¿Ü¼öÁ¤(IVF)(IVF) ±â¼úÀÇ ÃÖ±Ù ¹ßÀüÀº ºÒÀÓ Ä¡·áÀÇ Àü¸ÁÀ» ¹Ù²Ù°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ½ºÅ©¸®´×ºÎÅÍ ¹è¾ÆÀÇ Å¸ÀÓ·¦½º ÃÔ¿µ, ÀΰøÁö´É ¹× ¹è¾ç¾×ÀÇ °³·®¿¡ À̸£±â±îÁö, ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ºÒÀÓ¿¡ °í¹ÎÇÏ´Â Ä¿Çÿ¡°Ô Èñ¸ÁÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ü¿Ü¼öÁ¤(IVF) ºÐ¾ß¸¦ º¯È½ÃŰ°í ¼º°ø·üÀ» ³ôÀ̰í Àü¹ÝÀûÀΠȯÀÚ °æÇèÀ» Çâ»ó½ÃŰ´Â ÃÖ÷´Ü ±â¼ú°ú ±â¼úÀ» ³ªÅ¸³À´Ï´Ù.
Áøº¸ ¼³¸í
Âø»ó Àü À¯ÀüÇÐÀû °Ë»ç(PGT) PGT´Â Âø»ó Àü¿¡ ¹è¾Æ¸¦ ½ºÅ©¸®´×Çϰí À¯ÀüÀÚ ÀÌ»óÀ» È®ÀÎÇÏ´Â °ÍÀ¸·Î, °Ç°ÇÑ ¹è¾Æ¸¦ ¼±ÅÃÇÏ¿© Àӽмº°øÀÇ °¡´É¼ºÀ» ³ôÀÔ´Ï´Ù.
Timelapse ¹è¾Æ À̹Ì¡ Timelapse ±â¼úÀ» »ç¿ëÇÏ¿© ¹è¾ÆÀÇ ¹ß´ÞÀ» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÔÀ¸·Î½á ¼ºÀå ÆÐÅϰú ÀÌÁ¤Ç¥¸¦ ±â¹ÝÀ¸·Î ÇÑ º¸´Ù ÁÁÀº ¹è¾Æ ¼±ÅÃÀÌ °¡´ÉÇØÁ® ü¿Ü¼öÁ¤(IVF)ÀÇ ¼º°ø·üÀÌ Çâ»óµË´Ï´Ù.
ÀΰøÁö´É(AI) ¹× ¸Ó½Å·¯´× AI ¹× ¸Ó½Å·¯´×Àº IVF °á°ú¸¦ ÃÖÀûÈÇÏ°í °³ÀÎÈµÈ Ä¡·á Á¦¾ÈÀ» Á¦°øÇϱâ À§ÇØ È¯ÀÚ µ¥ÀÌÅÍ¿Í ¹è¾Æ ¹ß´ÞÀ» ºÐ¼®ÇÕ´Ï´Ù.
³¼Ò Á¶Á÷ µ¿°áº¸Á¸ ÀÌ ±â¼úÀº ¾Ï Ä¡·á ¹× »ý½Ä ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ±âŸ ÀÇ·á Ä¡·á¸¦ ¹Þ´Â ¿©¼ºÀ» À§ÇØ »ýÁ¸ °¡´ÉÇÑ ³ÀÚ¸¦ Æ÷ÇÔÇÑ ³¼Ò Á¶Á÷ÀÇ µ¿°áº¸Á¸À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
¹è¾ç¾×ÀÇ °³·® ¹è¾ç¾×ÀÇ °³·®¿¡ ÀÇÇØ ½ÇÇè½Ç¿¡¼ÀÇ ¹è¾ÆÀÇ ¹ßÀ°¿¡ ÀÌ»óÀûÀΠȯ°æÀ» ¸¸µé¾î ¹è¾ÆÀÇ ÁúÀÇ Çâ»ó°ú ü¿Ü¼öÁ¤(IVF)ÀÇ ¼º°ø·üÀÇ Çâ»óÀ¸·Î À̾îÁý´Ï´Ù.
³ÀÚ µ¿°á ±â¼ú ±Þ¼Ó µ¿°á ¹æ¹ýÀÎ À¯¸®È ¹æ¹ýÀº ³ÀÚ µ¿°áÀÇ ¼º°ø·üÀ» Çâ»ó½ÃŰ°í ¿©¼º¿¡°Ô ÀӽżºÀ» À¯ÁöÇϱâ À§ÇÑ ´õ ¸¹Àº ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.
´ÜÀÏ ¹è¾Æ À̽Ä(SET) ´ÙÅ ÀÓ½ÅÀÇ À§ÇèÀ» ÁÙÀ̱â À§ÇØ SET´Â ½ÅÁßÇÏ°Ô ¼±ÅÃµÈ ÇÑ ¹è¾Æ¸¦ À̽ÄÇÏ¿© ÇÕº´ÁõÀ» ÃÖ¼ÒÈÇÏ¸é¼ ³ôÀº ¼º°ø·üÀ» À¯ÁöÇÕ´Ï´Ù.
¶ÇÇÑ ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ´ë±â¾÷Àº ü¿Ü¼öÁ¤(IVF)À» ÃÖÀûÈÇÏ´Â ½Å±â¼úÀ» °³¹ßÇÏ¿© °æÀï ¿ìÀ§¸¦ È®º¸Çϰí ÀÖ½À´Ï´Ù. 2022³â 10¿ù ¹Ì±¹ÀÇ ÀÇ·á±â±â Á¦Á¶¾÷üÀÎ Alife Health»ç´Â µ¥ÀÌÅÍ ÁÖµµÀÇ ÀλçÀÌÆ®°ú ÀΰøÁö´É(AI)À» Ȱ¿ëÇÏ¿© ü¿Ü¼öÁ¤(IVF)¿¡ Çõ¸íÀ» ÀÏÀ¸Å°µµ·Ï ¼³°èµÈ Á¦Ç°±ºÀÎ Alife Assist Ç÷§ÆûÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ç÷§ÆûÀº ü¿Ü¼öÁ¤(IVF)ÀÇ ÁÖ¿ä ´Ü°è¿¡¼ ÀÓ»ó °áÁ¤À» Áö¿øÇÏ°í ºÒÀÓ Ä¡·á Ŭ¸®´ÐÀÇ ¾÷¹«¸¦ °£¼ÒÈÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Stim Assist, Embryo Assist, Insights·Î ±¸¼ºµÈ ÀÌ Çõ½ÅÀûÀÎ Ç÷§ÆûÀº »ý½Ä ³»ºÐºñÇÐÀÚ, ¹è¾Æ ¹è¾ç»ç, Ŭ¸®´Ð °ü¸®ÀÚ¿¡°Ô Á¾ÇÕÀûÀÎ Áö¿øÀ» Á¦°øÇÏ¸ç ¹è¾Æ µî±Þ, ¾à¹° Åõ¿© ¹× ½Ç½Ã°£ ¼º´É ¸ð´ÏÅ͸µ °³¼±ÇÏ°í °á±¹ ȯÀÚÀÇ Ã¼°¨°ú ü¿Ü¼öÁ¤(IVF)ÀÇ ¼º°ø·üÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ¹Ì·¡ ½ÃÀå ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
ÀýÂ÷ ±â¹Ý ÀλçÀÌÆ®
ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀåÀº º¸Á¶»ý½Ä±â¼ú, Àΰø¼öÁ¤, ºÒÀÓ ¼ö¼ú·Î ºÐ·ùµË´Ï´Ù. º¸Á¶»ý½Ä±â¼ú ºÐ¾ß´Â 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. 2023-2031³â »çÀÌ¿¡ °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º¸Á¶»ý½Ä±â¼ú ºÐ¾ß´Â ¶ÇÇÑ Ã¼¿Ü¼öÁ¤(IVF)°ú ³¼¼Æ÷Áú ³» Á¤ÀÚ ÁÖÀÔÀ¸·Î ±¸ºÐµË´Ï´Ù.
ȯÀÚ À¯Çü¿¡ µû¸¥ ÀλçÀÌÆ®
ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀåÀº ȯÀÚ À¯Çü¿¡ µû¶ó ³²¼º°ú ¿©¼ºÀ¸·Î À̺е˴ϴÙ. 2023³â ½ÃÀå Á¡À¯À²Àº ¿©¼º ºÎ¹®ÀÌ ´õ Å®´Ï´Ù. ±×·¯³ª ³²¼º ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ´õ ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº° ÀλçÀÌÆ®
ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀåÀº ºÒÀÓ Ä¡·á ¼¾ÅÍ, º´¿ø, ¼ö¼ú Ŭ¸®´Ð µîÀ¸·Î ±¸ºÐµË´Ï´Ù. ºÒÀÓ Ä¡·á ¼¾ÅÍ ºÎ¹®Àº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç 2023-2031³â¿¡ °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
´ë±â¾÷Àº ºñÁî´Ï½º ±âȸ¸¦ Àâ±â À§ÇØ »ç¾÷ È®´ë, Á¦ÈÞ, ½ÅÁ¦Ç° Ãâ½Ã, ½Å±Ô °í°´Ãþ ȹµæ µîÀÇ Àü·«À» ½Ç½ÃÇß½À´Ï´Ù.
2022³â 12¿ù, Care Fertility GroupÀº ¹Ì±¹°ú ½ºÆäÀÎÀ¸·Î ÁøÃâÇÏ¿© ¼¼°è Àü°³¸¦ È®´ëÇß½À´Ï´Ù.
2022³â 11¿ù, Mackay Specialist Day HospitalÀº »õ·Î¿î Virtus Rapid Access Endoscopy ClinicÀÇ °³¿øÀ» ¸ÂÀÌÇß½À´Ï´Ù.
2022³â 10¿ù, Indira IVF´Â ¹Ì±¹À» ±â¹ÝÀ¸·Î ÇÑ ¿©¼º°ú °¡Á·ÀÇ °Ç°À» Àü¹®À¸·Î ÇÏ´Â Maven Clinic°ú ¿ø°Ý ÀÇ·á ±â¹ÝÀÇ °¡»ó Ŭ¸®´ÐÀ» ÀÌ¿ëÇÏ¿© Á¦ÈÞÇß½À´Ï´Ù. ÀÌ Á¦ÈÞ´Â ÀεµÀÇ Maven ȸ¿ø¿¡°Ô Indira IVFÀÇ °íǰÁú ÀÓ»ó ÄÉ¾î ¹× ±âŸ ÇýÅÃ, Maven Ç÷§ÆûÀ» ÅëÇØ ÀÌ¿ë °¡´ÉÇÑ ÃÖ°íÀÇ °¡»ó °¡Á· ±³À° Äɾ Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù. Indira IVF´Â Àεµ¿¡ º»»ç¸¦ µÐ ºÒÀÓ Ä¡·á Àü¹® Ŭ¸®´Ð üÀÎÀÔ´Ï´Ù.
2022³â 8¿ù, Genea Fertility´Â Australian Jewish Fertility Networks(AJFN)ÀÇ ¿¬Â÷ ´ë±¸ ¸ð±Ý Ȱµ¿¿¡¼ ¹é±Ý ÈÄ¿øÀÚ·Î ºÀ»çÇß½À´Ï´Ù.
¹Ì±¹ ½ÄǰÀǾ౹, Áúº´°ü¸®¿¹¹æ¼¾ÅÍ(CDC), ¼¼°èÁúº´ºÎ´ãÁ¶»ç´Â ºÒÀÓ Ä¡·á ¼ºñ½º ½ÃÀ庸°í ½Ã¿¡ ÂüÁ¶ÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸ Áß ÇϳªÀÔ´Ï´Ù.
According to our new research study on "Fertility Services Market Forecast to 2031 - COVID-19 Impact and Global Analysis - by Procedure, Patient Type, End User," the market is anticipated to grow from US$ 32.99 billion in 2023 to US$ 67.12 billion by 2031; it is estimated to register a CAGR of 9.3% during 2023-2031. Market growth is attributed to the growing social and environmental factors and increasing prevalence of gynecological conditions. Growing technological advancements in in-vitro fertilization (IVF) process are likely to provide growth opportunities for the fertility services market. However, high costs associated with fertility services hinder the growth of the hyperbaric oxygen therapy market.
Treatments for genetic disorders and infertility problems are part of fertility services to aid conception. The development of assisted reproductive technologies (ART) such as intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), is one of the most significant developments in the fertility services market. These techniques have revolutionized reproductive medicine by making conceiving an embryo outside the body possible, thereby increasing the likelihood of a healthy pregnancy. Other advances include pre-implantation genetic testing, embryo cryopreservation, and egg freezing, providing additional options for couples and individuals pursuing fertility treatments.
Asia Pacific accounted for a major share of the global fertility services market in 2023. The Asia Pacific fertility services market is segmented into the China, Japan, India, South Korea, Australia, rest of Asia Pacific. The introduction and rapid distribution of several infertility drugs drive the market growth in this region. Increasing research activities in infertility treatments are predicted to open up new opportunities for the regional market in the coming years. Furthermore, the US held the largest share of the North American market. Changing lifestyles with increasing trends of unhealthy diets leading to infertility and gynecological disorders in men and women are responsible for the market growth.
Growing Technological Advancements in In-Vito Fertilization (IVF) Process Fuels the Fertility Services Market Growth Opportunities
Recent advances in IVF technology are changing the landscape of fertility treatment. From genetic screening to time-lapse imaging of embryos to artificial intelligence and improved culture media, these innovations offer hope for couples struggling with infertility. These advances represent cutting-edge technologies and techniques transforming the field of in vitro fertilization, increasing success rates, and improving the overall patient experience.
AdvancementExplanation
Preimplantation Genetic Testing (PGT)PGT allows for the screening of embryos to identify genetic abnormalities before implantation, increasing the chances of a successful pregnancy by selecting healthy embryos.
Time-lapse Embryo ImagingContinuous monitoring of embryo development using time-lapse technology allows for better embryo selection based on growth patterns and milestones, improving IVF success rates.
Artificial Intelligence (AI) & Machine LearningAI and machine learning analyze patient data and embryonic development to provide personalized treatment recommendations, optimizing IVF outcomes.
Ovarian Tissue CryopreservationThis technology enables the freezing and preservation of ovarian tissue, containing viable eggs, for women undergoing cancer treatment or other medical procedures that affects fertility.
Improved Culture MediaAdvanced culture media formulations create an ideal environment for embryo development in the lab, leading to higher embryo quality and better IVF success rates.
Egg Freezing TechniquesVitrification, a rapid freezing method, has improved egg-freezing success rates, giving women more options for preserving their fertility.
Single Embryo Transfer (SET)Reducing the risk of multiple pregnancies, SET involves transferring a single carefully selected embryo, maintaining high success rates while minimizing complications.
Further, large companies operating in the fertility services market are developing new technologies to optimize IVF and thus gain a competitive advantage. In October 2022, a US-based medical device manufacturer, Alife Health, launched the Alife Assist platform, a range of products designed to revolutionize IVF by leveraging data-driven insights and artificial intelligence (AI). The platform helps in supporting clinical decision-making during key IVF phases and streamline fertility clinic operations. This innovative platform, consisting of Stim Assist, Embryo Assist, and Insights, provides comprehensive support to reproductive endocrinologists, embryologists, and clinic administrators to improve embryo grading, drug dosing, and real-time performance monitoring, ultimately improving patient experience and IVF success rates. Such advancements are expected to provide opportunities for the market growth in future.
Procedure -Based Insights
Based on procedure, the fertility services market is segmented into assisted reproductive technology, artificial insemination, and fertility surgeries. The assisted reproductive technology segment accounted for the largest market share in 2023. It is expected to register the highest CAGR during 2023-2031. The market for the assisted reproductive technology segment is further segmented into in vitro fertilization and intracytoplasmic sperm injection.
Patient Type -Based Insights
The fertility services market, based on patient type, is bifurcated into male and female. The female segment held a larger market share in 2023. However, the male segment is anticipated to register a higher CAGR during the forecast period.
End User -Based Insights
In terms of end user, the fertility services market is segmented into fertility centers, hospitals & surgical clinics, and others. The fertility centers segment held the largest market share in 2023 and is anticipated to register the highest CAGR during 2023-2031.
Leading players are implementing strategies such as expansion, partnership, launch of new products, and acquisition of a new customer base for tapping prevailing business opportunities.
In December 2022, Care Fertility Group expanded its global reach by entering into the US and Spain.
In November 2022, Mackay Specialist Day Hospital welcomed the opening of the new Virtus Rapid Access Endoscopy Clinic.
In October 2022, Indira IVF collaborated with Maven Clinic, a US-based company specializing in women's and family health with the help of telemedicine-based virtual clinics. The collaboration aimed to provide Maven members in India access to Indira IVF's high-quality clinical care, other benefits, and the best virtual family education care available through the Maven platform. Indira IVF is an India-based chain of specialty infertility clinics.
In August 2022, Genea Fertility was a Platinum Sponsor at the Australian Jewish Fertility Network's (AJFN) Annual Major Fundraiser.
The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the fertility services market report.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies